In This Section

Continuing Medical Education

Accreditation Statement

The American Association for Cancer Research (AACR) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education activities for physicians.


Credit Designation Statement

AACR has designated this live activity for a maximum of 14.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Credit certification for individual sessions may vary, dependent upon compliance with the ACCME Accreditation Criteria. The final number of credits may vary from the maximum number indicated above.

Claiming CME Credit

Physicians and other health care professionals seeking AMA PRA Category 1 Credit(s)TM for this live continuing medical education activity must complete the online CME Request for Credit Survey by November 9, 2020. Certificates will only be issued to those who complete the survey. The Request for Credit Survey will be available via a link on this web page and via email. Your CME certificate will be sent to you via email after the completion of the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 14.5 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.  

To receive ABIM MOC, participants must request MOC in the CME Request for Credit Survey and complete all questions. Once these steps are completed, AACR will submit your completion information via the ACCME’s Program and Activity Reporting System for the purpose of granting MOC points.

Statement of Educational Need, Target Audience, and Learning Objectives

The core goals for clinicians and oncologists in combating endometrial cancer are prevention, screening, classification, and treatment. This conference will focus heavily on classification and treatment and future iterations will focus on prevention as well.

Current promising research includes continuing efforts towards improved molecular stratification of endometrial tumors. Classification based upon gene expression patterns can have important prognostic implications. Improved classification can better inform treatment. Enhanced genetic profiling methods are underway to more rapidly aid oncologists by linking genetic signatures to diagnosis and prognosis and bringing patients into the appropriate clinical trials.

Next-generation sequencing is being used to analyze circulating and shed tumor cells in order to identify new biomarkers. These new biomarkers are then studied to determine usefulness in diagnosis, prognostication, and prediction of response to therapy. Novel universal gene mutations that could be acting as cancer drivers are being discovered, which can then be evaluated as drug targets. Furthermore, using genomic and proteomic analysis to detect correlation between gene profiles and outcomes can inform outcomes and risk.

One of the goals of these research efforts is to elucidate the mechanisms by which endometrial cancer can develop, grow, and spread, and apply that knowledge to novel model systems. Model systems allow researchers to recapitulate a cancer state and subsequently determine how best to treat that cancer in order to bring treatments to clinical trials. Newer model systems, such as organoids, allow faster recapitulation and faster results in systems that are more human-like than some animal models.

Immunotherapy and targeted therapies are also being researched for use in women with endometrial cancer. Understanding ways of utilizing the body’s immune system to fight cancer is one of the most promising areas of cancer research. Specifically, endometrial cancer cells are adept at uploading checkpoint molecules that turn off the immune response, and so, checkpoint blockade represents a burgeoning avenue of possibility for endometrial cancer treatment.

Targeted therapy is a fairly new avenue of treatment for endometrial cancer and new research is underway to explore more ways to improve patient outcomes. Typical targets include mTOR and VEGF along with other proteins and kinases typically responsible for cell growth, division, and angiogenesis. Combinations of checkpoint blockade and targeted therapies to block growth factors represent the newest and potentially most promising avenue of treatment for late stage and recurrent/resistance endometrial cancer.

This conference will bring together endometrial cancer researchers and industry professionals with clinician scientists and clinicians who are currently treating patients to ensure that any new targets, biomarkers, and model systems are being explored. For physicians and oncologists to best aid patients, they must have a solid and current understanding of the most novel biomarkers and new advances taking place in the lab that can eventually be applied to the clinic. Physicians will leave this conference with knowledge of novel advancements in endometrial cancer targets in the lab and the potential thereof for therapeutic applications. New research is going to be a focus of the conference, with the ultimate goal of informing treatment. Therefore, this conference will be of interest to oncologists who specialize in endometrial cancer, as well as researchers who are working towards new discoveries and treatments.

After participating in this CME activity, physicians should be able to:

  1. Identify novel strategies for stratifying endometrial tumors.
  2. Evaluate novel biomarkers to assess patients’ individual cancer, potential responses to treatment, and to personalize therapy.
  3. Analyze novel genetic mutations that could be acting as cancer drivers.
  4. Integrate novel immunotherapies, targeted therapies, and combination therapies for personalized cancer treatment.
  5. Integrate next-generation omics approaches to enhance genetic profiling methods, leading to more effective treatment.
  6. Identify novel model systems to recapitulate endometrial cancer and identify novel drug targets.

Disclosure Statement

It is the policy of the AACR that the information presented at AACR CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, AACR will provide information that Scientific Program Committee members and speakers have disclosed about financial relationships they have with commercial entities that produce or market products or services related to the content of this CME activity. This disclosure information will be made available on this webpage.

Acknowledgment of Financial or Other Support

The AACR gratefully acknowledges the following commercial supporters:.

PROFESSIONAL EDUCATION GRANT

GlaxoSmithKline

Questions about CME?

Please contact the Office of CME at (215) 440-9300 or [email protected].